It has been well established that the expression of a particular idiotype (Id) ~ on antibodies of a given specificity is often linked to the Igh-C gene complex that determines the allotype markers of the Ig heavy chain constant region (l). This has been particularly well documented in the anti-a(1-3) dextran (Dex) system which in fact serves as a model reference system for this rule (2, 3) . Previous studies have thus indicated that BALB/c (Igh-C a) mice immunized with Dex B1355 [35% a (1) (2) (3) , 8% a (1) (2) (3) (4) , and 57% a(1-6)] (4) respond with ;kl-bearing antibodies directed almost exclusively against the a(1-3) linkage (2) . As much as 50% of these antibodies express the cross-reactive idiotype (IdX) (5) that has been defined with reference to a(1-3) Dex-binding BALB/c myeloma and hybridoma proteins (6) . The structural correlates of this Id have been recently defined by a comparison of the amino-acid sequence of the heavy chain variable region (Vn) of a panel of IdX-positive and IdX-negative a(1-3) Dex-binding myeloma and hybridoma proteins from BALB/c mice (6) . These elegant studies have identified two amino acids in positions 54 and 55 of the second V~ hypervariable region which determine ldX expression.
The strict linkage of IdX expression with the Igh-C ~ allotype marker has been demonstrated by the incapacity of mice of other heavy chain linkage groups to synthesize anti-a(l-3) Dex antibodies expressing this Id (2, 3) . For example, C5781/6 (Igh-C ~') mice do not respond with detectable amounts of such antibodies. Their antia(1-3) Dex antibodies bear the i¢ chain in the primary response to B1355, and although they switch to ~l-bearing antibodies when hyperimmunized, these antibodies still do not express IdX (7) . It has been proposed that this immune status reflects an absence of the structural V, Dex gene in these mice (7) . In contrast, this gene would be present in all Igh a haplotype strains, where it codes for IdX.
Related studies in other idiotypic systems indicate however, that these relations may not always obey strict rules (8, 9) . The nonexpression of gene products may only be apparent when they are probed by standard immunization procedures. Mechanisms based on Id recognition (10) may in some instances activate clones that otherwise remain silent or nonexpressed (11) (12) (13) (14) . In some idiotypic systems in the mouse, recent studies have demonstrated that after immunization by anti-Id it was possible to induce detectable amounts of Ig (13) or antibodies (11, 12) expressing a reference Id in animals that could not express this Id upon conventional immunization with antigen.
In the present study we tested this approach using as a model the a(l-3) Dex system. Our results indicate that substantial amounts of ~t~-bearing, IdX-positive Ig (Ab3), and a(l-3) Dex-binding antibodies (Abl') appear in C.B20 and C57B1/6 (Igh-C b) mice after treatment with rabbit anti-IdX antibodies (Ab2). Contrary to BALB/ c mice immunized with Dex B1355, a significant fraction of this response was of the IgG1 class. The purified C.B20 Abl' antibodies differed however from the BALB/c antibodies (Abl) in Dex-binding specificity, and the IdX-positive IgG1 antibodies expressed the Igh4 b allotype determinants.
Materials and Methods
Mice. C57B1/6 and C57B1/10 (Igh-C b) mice were obtained from the Centre de sfilection des animaux de laboratoire, Orlfians, France. The C.B20 (Igh-C b, H2 d) congenic strain was obtained from Dr. M. Potter, National Cancer Institute, National Institutes of Health, Bethesda, MD. BALB/c (Igh-C a, H2 d) and SJL/J (Igh-C b) mice were obtained from our breeding facilities at the Institut de Recherche Scientifique sur le Cancer. BAB/14 (Igh-C b) mice were provided by Texas, Dallas, TX, and hybridoma R16-7 was from Dr. A. Nisonoff, Brandeis University, Waltham, MA. These proteins were purified on columns of protein A-Sepharose. The pH of the etuting buffer was optimal for the respective classes of these proteins, as specified by Ey et al. (17) . Purified UPC-10 was purchased from Litton Bionetics Inc., Kensington, MD. Ascites fluids containing the Igh4 b myeloma protein MOPC-245 (M245) was from Dr. M. Potter. The protein was purified on a column of protein A-Sepharose (17) .
Purification of Induced Anti-c~ (1) (2) (3) Dex Antibodies. Dextran B 1355-or Ab2-induced antibodies were purified on mini-columns consisting of 1-ml capacity disposable plastic tips packed with 200-500 ~1 of B1355-Sepharose or B512-Sepharose gels. After passing through 0.2-1 ml of the test serum and washing until OD (280 nm) was ~<0.02, the bound antibodies were eluted with 0.2 N glycine buffer, pH 2.8, and collected into 2% bovine serum albumin, 0.05 M phosphate buffer (BSA-PO4), pH 8.0. All procedures were carried out at 4°C.
Anti-IdX
Antibodies. An anti-IdX reagent specific for the public Id shared by IdX-positive a(l-3) Dex-binding antibodies was prepared from the serum of rabbit 314 immunized with the J558 myeloma protein. Antiisotype antibodies were removed by absorption with the following myeloma proteins coupled to cyanogen bromide-activated Sepharose 4B: Fab MOPC-173 (M173) (y2~, ~¢); MOPC-21 (M21) (y~, x); HOPC-1 (yz,, h~); HOPC-8 (a, x); A2 (y~, x). The purification of Fab M173, M21, HOPC-1, and A2 was as described elsewhere (14) . The antibodies in the effluent serum were purified on a column of M104E-Sepharose. They were dialyzed against phosphate-buffered saline and concentrated to 3 mg/ml on Amicon CF50 membranes (Amicon Corp., Danvers, MA). Some batches of antibodies were reabsorbed on the HOPC-1 column to remove residual anti-X~ antibodies.
The idiotype-binding capacity (IBC~0) of these antibodies, as determined by the indirect precipitation method described by Kuettner et al. (18) , was 0.77 IBCs0//.tg of purified antibodies. Binding-site inhibition assays indicated 40% inhibition by Dex B1355 of the binding of 125Ilabeled J558 to microplates coated with these antibodies. Dex B512 or panose were not inhibitory.
Allogeneic anti-Id antibodies were prepared by immunizing C57B1/6 mice with J558 myeloma protein coupled to the keyhole lympet hemocyanin (KLH) (19) . The serum was first absorbed on a column of HOPC-8 (a, tc)-Sepharose to remove anti-Igh2 a antibodies, and the antibodies were purified on a column of J558-Sepharose. 75% of the antibodies were directed to the J558 IdI, and 25% to the J558 IdX, as determined in an indirect hemagglutination assay (20) using J558-and M104E-coupled sheep erythrocytes. Binding-site inhibition assays gave 75% inhibition by Dex B1355. The IBCs0 content was 1.86 IBC~0/#g of purified antibodies.
A syngeneic BALB/c anti-J558 serum was a gift of Dr. P. A. Cazenave, Institut Pasteur, Paris, France. The anti-J558 antibodies were purified on a column of J558-Sepharose.
Rabbit Anti-Mouse Heavy and Light Chain Reagents. Affinity-purified anti-K, anti-Fc/x, anti-y1, and anti-yz antibodies were obtained by previously described methods (15) . Anti-,ka antibodies were purified from an anti-M104E (#, XI) serum. The serum was preabsorbed on columns of Fab M173, M21, and TEPC-183 (kt, ~¢) coupled to Sepharose, and the antibodies were purified on a column of HOPC-1. Anti-y3 antibodies were obtained from an anti-J606 ('/3, ~) serum preabsorbed on columns of Fab M173, M173, and M21, and the antibodies were purified on a column of FLOPC-21 (y3, ~¢). Anti-a antibodies were obtained from an anti-TEPC-15 (a, x) serum preabsorbed on columns of Fab M173 and M21, and the antibodies were purified on a column ofJ558 (a, ~1). The specificity of these reagents was verified in indirect radioimmune binding assays (18) using a panel of myeloma proteins representative of various Ig classes. Whenever required the purified reagents were reabsorbed on appropriate columns. hnmunization of Mice with Antiidiotype Antibodies. Anti-IdX J558 antibodies from rabbit 314 were coupled to KLH by means of glutaraldehyde according to Bona et al. (19) . One group of five C.B20 mice was immunized with Ab2-KLH. The mice received a total of five injections, each containing 150 p.g of Ab2-KLH, the first in complete Freund's adjuvant (CFA), the second in incomplete Freund's adjuvant, and the remaining three in saline. Two other groups of C.B20 mice, group 2 (five mice) and group 3 (eight mice), received only the first two injections of Ab2 antibodies, which were not coupled to KLH. The group 2 mice received 150 #g, and group 3 mice, 100 p.g per injection. One group of five C57B1/6 mice received two injections of 150/~g of Ab2-KLH. Equal numbers of control mice in each group were identically immunized with normal rabbit IgG (NRablgG) (Pentex Biochemicals, Kankakee, IL) absorbed on a column of J558-Sepharose. Lastly, one group of six C.B20 mice were immunized with two injections (80 ~tg) of allogeneic C57BL/6 anti-J558 antibodies coupled to KLH.
Radiolabeting. Myeloma proteins and antibodies were radiolabeled with ~25! according to the method of Greenwood and Hunter as modified by Cuatrecasas and Hollenberg (2t) . The specific radioactivity ranged between 0.5 and 3 X 106 cpm//~g. Radioimmunoassay (RIA) for the IdX Idiotype. The IdX determinant was measured by a competitive inhibition RIA as described by Hansburg et al. (5) . In brief, serial dilutions of test serum or affinity-purified antibotties were tested for their capacity to inhibit the binding of 12sIlabeled M104E (4 ng, ~4,000 cpm) to 96-well polyvinyl chloride microplates (Dynatech Laboratories, Inc., Alexandria, VA) coated overnight with affinity-purified anti-IdX 558 antibodies at 1.5 /xg/ml in 10 /zg/ml BSA-PO4. After overnight incubation at 37°C, the microplates were washed and the radioactivity was estimated in a gamma counter. The use of the heterologous M104E protein with the anti-J558 reagent ensured that the assay measured the IdX determinant, since the two a(1-3) Dex-binding myeloma proteins share this public determinant but differ in their respective IdI determinants (6) . The amount of IdX was estimated with reference to a standard inhibition curve constructed with unlabeled M 104E. A maximum of 60-70% of added counts were bound to the wells, with background binding ~0.5% of added counts.
The IdX assay using the syngeneic anti-J558 antibodies was carried out by the competitive RIA described by Bosma et al. (22) . This involved precoating the wells with MI04E (0.25/.tg/ ml in BSA-PO4), followed by incubation with anti-J558 antibodies (1.5 ~g/ml in 0.5% BSA, pH 8.0). The remainder of the assay was performed as described above. RIA for the Igh4 and ]gh4 Allotype. Igh4 allotype determinants were estimated using a competitive RIA described by Bosma et al. (22) . Microplates were coated with 10/_tg/ml of M245 (Igh4 b) in BSA-PO4 followed by a 3 d incubation with a 1:40 dilution of a BALB/c anti-C57B1/6 Ig serum (a gift of Dr. M. Bosma, Fox Chase Institute, Philadelphia, PA). Radiolabeled M245 (2.5 ng, ~25,000 cpm) was added together with dilutions of test sera. A standard curve was constructed with unlabeled M245. The microplates were incubated overnight at 37°C, washed, and the radioactivity was estimated. For Igh4 a allotype determinants, microplates were coated overnight with specifically purified C57B1/6 anti-BALB/c Igh4 a antibodies (6 btg/ml in BSA-PO4). Myeloma protein M21 (Igh4 a) was used as the standard and radiolabeled ligand (4 ng, ~4,000 cpm). From here on, the assay was carried out as above.
RIA for Anti-v~ (1 3) and Anti-o~(l-6) Dex Antibodies. The titer of these antibodies was estimated by a solid-phase binding assay on 96-well microplates as descr/bed in detail by Geckeler et al. (23) . For anti-a(l-3) determination, serial dilutions of sera or purified antibodies and the M104E myetoma protein standard (concentration range, 0.31-25 ng/t00 #1) were incubated in duplicate (18 b, 24°C) on plates coated with 200/sg/m[ of Dex BI355_ This was followed by a 6-h incubation at 37°C with a predetermined saturating dose of 12r'I-labeled anti-)11 antibodies (15 ng/100 #1, ~30,000 cpm). Independent experiments using 12~I-labeled M 104E or J558 indicated that ~75% of the added counts were bound to the B1355-coated plates.
For anti-a(l-6) determination, B512-coated plates were used, and the standard was the W3129 (anti-a(l-6) Dex myeloma protein). In this case, ~2~I-labeled anti-~ antibodies were used in place of the anti-N~ reagent.
The values were read on the linear portion of the standard binding curves and were expressed as #g/ml of anti-Dex antibodies. Threshold detectability of antibodies in the two assays was 0.5 /Lg/ml of serum. Background binding (omission of the sera or Dex) was ~2% of the added radiolabeled anti-light chain antibodies and was substracted from all values.
RIA for Class Composition of Purified Anti-Dex Antibodies. Whereas the preceding assay was designed to measure the total amount of either )~l-bearing or K-bearing anti-Dex antibodies, the present assay was designed to determine the relative heavy chain class representation of these antibodies. This assay was essentially similar to that above, except that the antibodies bound to the Dex-coated plates were detected using an excess of I25I-labeled heavy chain class-specific reagents. The percentage of each antiisotype bound was calculated from the following formula: RIAfor Class Composition ofAb3 Ig. This was carried out using a microplate-binding assay as described above for the class composition of antibodies, except that the microplates were precoated with rabbit anti-IdX 558 antibodies (1.5 #g/ml in BSA-PO4). Before incubation, the test sera were absorbed on columns of Dex B 1355 and B512 to remove anti-Dex antibodies and additionally with NRabIgG-Sepharose gels to remove anti-rabbit IgG antibodies. Such antibodies were present in large amounts in all mice immunized with the rabbit Ab2. Their thorough elimination was essential in this assay and was verified in each experiment by a parallel incubation on NRabIgG-coated wells (control binding). The percentage of each antiisotype bound per milliliter of test serum was calculated from the same formulas as used for the anti-Dex antibodies (see above).
Results
Specificity of the Anti-IdX Antibodies. The specificity of the rabbit anti-IdX 558 reagent was verified using as competitors a panel of myeloma and hybridoma proteins that have various antigen-binding activities. As can be seen in Fig expression. The present reagent is thus similar to the one used by Clevinger et al. (6) which allowed the authors to distinguish IdX expression on these monoclonal antibodies, The specificity of the reagent was further tested by using as competitors a panel of Ar-, NP-, galactan-, PC-, and inulin-binding myeloma and hybridoma proteins as well as a panel of 220 ascites fluids containing various myeloma proteins. A single ascites fluid was found inhi'bitory. This contained protein TEPC-1072, a #, X1 weak anti-c~(l-3) Dex-binding myeloma protein (M. Potter, personal communication).
The subsequent experiments were designed to test the in vivo functional properties of these antibodies with respect to their capacity to induce an IdX-positive response in C57B1/6 and C.B20 mice.
Induction of ldX-positiee tg in C. B20 and C57Bl/6 Mice. Groups of C.B20 and C57B1/ 6 mice (23 mice in all; see Materials and Methods) were injected with rabbit ant~-IdX 558 (Ab2) in CFA. The controls consisted of equal numbers of mice injected with NRabIgG. 7 d after the last injection, the sera of these animals were tested in the IdX assay, and the results are shown in Fig. 2 . The sera of all mice that received Ab2 completely inhibited the binding of 125I-labeled M104E to anti-IdX 558-coated microplates, while no significant inhibition was obtained with either their pre-immune sera or the sera of mice immunized with NRablgG. Similar results were obtained in an IdX assay that used syngeneic anti-J558 antibodies (not shown).
In view of the early collection time of the sera, there remained a possibility that residual rabbit anti-IdX was responsible for the inhibitions observed. Indeed, we as well as others (24) radiolabeled ligand in such assays. Independent measurements of residual Ab2 administered as two 23 #g injections per mouse of 12~I-Ab2 in CFA into six normal C.B20 mice, indicated a rapid clearance from the serum; 30 ng/ml remained at 2 d, and 2 ng/ml remained at 7 d after the last injection.
In other experiments, individual sera were preabsorbed with myeloma proteins or rabbit anti-mouse antibodies coupled to Sepharose before being tested in the IdX assay. The results shown in Fig. 3 indicate that whereas the M 173-and J558-Sepharose gels removed marginal inhibitory activity, the rabbit anti-IdX and anti-~l gels removed most of the inhibitory activity. Some inhibitory activity was also removed by the anti-K and anti-a gels. The results strongly suggest that the small amounts of residual Ab2 did not compete in this assay since inhibitory activity would have been removed by the J558, not by the anti-IdX gel. Rather, these results suggest that Ig expressing a ~1 chain and the IdX determinant were responsible for most of the inhibition observed in the IdX assay.
In all, these results indicate that ~l-bearing, IdX-positive Ig were being generated soon after immunization with Ab2 antibodies. The titer and the kinetics of these IdXpositive Ig in individual weekly bleeds are shown in Fig. 4 . It can be seen that IdX levels, undetectable in pre-immunization sera, abruptly reached a value of 100-300 /~g/ml in C.B20 mice and 50-100 #g/ml in C57B1/6 mice 7 d after the last injection of Ab2 antibodies. The titers remained at a plateau during the 6 wk (C57B1/6) and 18 wk (C.B20) periods investigated.
When C.B20 mice were boosted with Dex B1355-Con A 18 wk after the last injection of Ab2, they responded with a sharp increase in the IdX titer (maximum, 150-350 #g/ml). This response however, was not observed in C57B1/6 mice ( Fig. 4 ). Control sera never contained >0.5-1 #g/ml of the IdX Id, values that are within the limits of the sensitivity of the assay.
The results indicate that the amount of IdX-positive Ig can be further increased upon boosting with B1355. Similar results were obtained in 13 Five mice were treated with anti-IdX (C.B20 anti-Ab2), and five control mice were treated with normal rabbit IgG (C.B20 anti-NRablgG) on the days indicated by the arrows (see Materials and Methods). On day 159 (C.B20 mice), and on day 56 (C57BI/6 mice), the animals were boosted with B1355 in CFA according to (2)~ B1355-Con A according to (7) , or E. coli according to (44) , Tbe antibody titer was estimated in a binding assay, and the IdX concentration by competitive RIA as described in Materials and Methods. Each point is the arithmetic mean -+ SD of individual determinations. immunized with only two injections of anti-IdX antibodies that were not coupled to KLH (see Materials and Methods).
Induction of IdX-positive Anti-a(l-3) Dex Antibodies (Abl') in C.B20 and C57Bl/6 Mice. The finding of this strong IdX-positive response suggested that some of the IdX-positive Ig carried a(l-3) Dex-specific activity. First, we tested the sera for total ~l-positive anti-a(1-3) Dex antibodies. The results of these experiments are shown in Fig. 4 .
Whereas anti-a(1-3) Dex antibodies were not detectable in significant amounts (41 ~g/ml) in either pre-immune bleeds or in the NRabIgG-treated control groups, such antibodies appeared in small but significant amounts in each animal pretreated with Ab2. The antibodies were detectable with a delay of 1-3 wk with respect to the IdX-positive Ig. The titers ranged from 15 to 40/~g/ml in the three groups of C.B20 mice and from 2 to 5 /zg/ml in C57B1/6 mice. In control animals conventionally immunized with B 1355 alone, some C57B1/6 mice, but none of the other Igh-C b mice, responded with high levels (30-100 #g/ml) of anti-a(1-3) Dex antibodies (not shown). However, as will be discussed below, these conventionally induced anti-a(1-3) Dex antibodies differed from the Ab2-induced antibodies in IdX expressi.on, in agreement with a previous study (7) .
These results indicate that immunization with Ab2 alone leads to the appearance of a low, but significant ~k~-positive anti-a(1-3) Dex response. The maximum titer of these antibodies is about one order of magnitude lower than the serum IdX titer.
Second, in order to determine whether these anti-a(1-3) Dex antibodies expressed the IdX determinant, the antibodies were affinity purified from pooled sera on columns of B1355-Sepharose, as described in Materials and Methods. The sera were preabsorbed on B512-Sepharose columns to eliminate anti-a (1-6) Dex antibodies that served as controls. Anti-a(1-6) Dex antibodies were also purified from control mice injected with NRabIgG. Each effluent serum fraction from these absorptions was also saved. Fig. 2 shows that purified C.B20 anti-a(1-3) Dex antibodies completely inhibited the binding of 125I-labeled M104E to rabbit anti-IdX 558. The inhibition curves overlapped with the standard M 104E myeloma protein inhibition curve, as well as with hyperimmune BALB/c anti-a(1-3) Dex antibodies. This inhibition pattern is suggestive of a high degree of idiotypic similarity. The data furthermore suggested that most, if not all, of these antibodies express the IdX idiotype. This was indicated by the fact that the inhibition curves varied within a factor of 0.8-1.2 in terms of weight of added competitor compared to the M 104E standard. An idiotypic deficiency would have been seen by a more pronounced shift of the curve to the right. Thus, Ab2-treatment generates an early IdX-positive anti-a(1-3) Dex response.
Anti-a(1-3) Dex antibodies purified from C.B20 mice boosted with B1355-Con A (Fig. 4) were indistinguishable from the above antibodies in IdX expression. In addition, Ab2 pretreatment in some way appeared to sensitize these animals to respond with substantial amounts of IdX-positive antibodies, as the antibody titer rose from an average of 20 to 30-150 btg/ml after B1355 boosting. In all, 10 pools of sera from three C.B20 groups that include pre-and post-B1355 boost bleeds and one pool from C57B1/6 mice (a pre-B1355 boost bleed) were tested, with similar results. Control Al-positive anti-a(1-3) Dex antibodies purified from conventionally immune C57B1/6 mice, some of which responded with up to 300 ~g/ml of antibodies, were devoid of inhibitory activity in the IdX assay.
Induction of ldX-positive Ig and Anti-e~(1-3) Dex Antibodies in C.B20 Mice Immunized with
Allogenezc Anti-J558 Ab2. A group of six C.B20 mice were injected twice at a 15 d interval with 80 gg/ml (150 IBCs0) of anti-J558 antibodies coupled to KLH. The magnitude of the IdX-positive Ig and the anti-a(1-3) Dex antibody responses was significantly lower in these animals compared with the groups immunized with rabbit Ab2. Only four mice responded, with an average of 8/zg/ml of IdX-positive Ig first detected as late as 6 wk after the second injection of Ab2. IdX expression in these sera was measured in the IdX assay that used the rabbit anti-IdX 558 reagent. Preimmune sera contained no detectable IdX-positive Ig or anti-a(1-3) Dex antibodies. Only two mice responded with low titers (2-4/.tg/ml) of )~l-positive anti-~(1-3) Dex antibodies. However, all mice responded with anti-cffl-3) Dex antibodies when boosted with B1355-Con A 11 wk after the last Ab2-injection, but still with low titers (average 9/*g/ml). It was difficult to purify sufficient amounts of these antibodies for the determination of their IdX expression.
Induction of ldX-positive Ig Devoid of Dex-binding Activity (Ab3).
The presence of such molecules was suggested by an inspection of the data presented in Fig. 4 which indicated a several-fold greater level of total IdX-positive Ig compared with IdXpositive anti-a(1-3) Dex antibodies, These Ig were assayed after thorough absorption of the sera on B 1355 and B512 columns. The effluents, which were verified as lacking detectable Dex-binding activity in a binding assay, were nevertheless found inhibitory in the IdX assay. The Ig differed, however, from the Ab 1' antibodies by the slope of their inhibition curve, which was suggestive of an idiotypic deficiency in spite of their capacity to completely inhibit the binding of 125I-labeled M104E to anti-IdX 558 (Fig. 2) .
Independent calculations gave the following relative amounts of Ab3 Ig and Abl' antibodies in whole sera. In the pre-B 1355-Con A boost bleeds of C.B20 and C57B1/ 6 mice, ~90% of the IdX-positive Ig represented Ab3. In post-B 1355 boost bleeds of C.B20 mice Ab3 and Abl' were about equally represented among IdX-positive Ig, while in C57B1/6 mice the proportion of Ab3 remained at 90% of the total IdXpositive Ig. For comparison, BALB/c hyperimmune sera contain only -3% of Ab3 Ig with the vast majority of the IdX-positive component being represented by the Abt anti-~(1-3) Dex antibodies.
Therefore, injection of Ab2 appears to generate at least two populations of IdXpositive Ig in these Igh-C b mice, Molecules lacking detectable Dex-binding activity are defined as Ab3, and molecules with intrinsic a(1-3) Dex-binding activity are defined as Abl'. Both definitions are used with reference to previous studies (24, 25) .
Effect of Ab2-treatment on the Anti-c~(1-6) Dex
Response. The responder status of Igh-C b mice with respect to the a(1-6) linkage of Dex is now well established (26, 27) . It was thus of importance to assess whether anti-IdX 558 administration had any effect on the quantity and quality of this response.
As shown in Fig. 4 the pre-immune level of anti-cffl-6) Dex antibodies (10-30/_tg/ ml) increased two to threefold whether the C.B20 and C57B1/6 mice were injected with Ab2 or NRabIgG. Boosting with B1355-Con A did not affect the relative antibody level, which rose to ~ 100/*g/ml in both groups.
The expression of IdX on these antibodies was examined in the IdX assay. As shown in Fig. 2 , anti-a(1-6) Dex antibodies purified from C.B20 mice treated with Ab2 or NRablgG were not inhibitory. However, antibodies purified from four other pools of Ab2-treated mice (but from none of the NRabIgG-treated groups) gave up to 70% inhibition at high concentrations (Fig. 2) .
Binding assays indicated that these sera contained ~5% of anti-or(i-3) Dex antibodies. Since, as mentioned above, all anti-a(1-3) Dex antibodies were IdX-positive, these results can be interpreted on the basis of a contamination by a small amount of copurified anti-a(1-3) Dex antibodies (Dex B512 contains 4% of a(1-3) glucosidic linkages [4] ).
The results indicate that the in vivo administered rabbit anti-IdX 558 had no significant effect on the normal course of the anti-a(1-6) Dex response.
Specificity of Abl' Antibodies for Various Dex. The finding that Abl' antibodies expressed the IdX determinant prompted a study of their Dex-binding specificity using a panel of eight Dex having different glucosidic linkages compositions (4) . In all, six serum pools or individual bleeds from Ab2-treated C.B20 mice, and one purified anti-a(1-3) Dex antibody sample were tested. The binding pattern obtained with the purified antibodies was typical of the results obtained with the serum samples, and is shown in Table I . Also shown is the binding pattern of purified antia(l-3) Dex antibodies from hyperimmune BALB/c mice and from conventionally hyperimmunized C57B1/6 mice, as well as the binding of the reference J558 and MI04E myeloma antibodies (28, 29) .
The C.B.20 and the BALB/c antibodies bound most strongly to Dex B1355, B1498S, and B1501S compared with the remaining five dextrans, B742S (C3R), B742L, B1375, B1255, B1254S(E). However, the C.B20 antibodies could be distinguished from the BALB/c antibodies in that they bound less strongly to these last five Dex. This is clearly evident from the calculations of their relative binding avidities. Table I also shows that the binding specificity of the J558 myeloma protein measured in the present assay is very similar to that of its reported specificity in a precipitin assay (28) . In contrast, purified )~l-positive IdX-negative conventional C57B1/6 antibodies have a very different binding pattern; they do bind to B1355, B1498S, and B1501S, but they do not bind at all to the remaining five Dex.
An element to be considered in such comparisons would appear to be the degree of polymerization of the antibodies as documented by previous work (30) . We have not detected significant differences in binding avidity in samples typed as high IgG1, low IgM vs. high IgM, low IgG 1 Ab 1' content (see below for the class composition of Ab 1' antibodies).
These experiments indicate that the Dex-binding specificity of C.B20 Ab 1' can be distinguished from that of the BALB/c antibodies. The C.B20 antibodies are, however, more closely related to the BALB/c than to the IdX-negative C57B1/6 antibodies.
Class Composition of the Abl' Antibodies and Ab3 Ig. Previous studies on the class composition of anti-a(l-3) Dex antibodies of BALB/c mice have demonstrated the striking class restriction of this response (31, 32) . Since the IdX-positive Abl' antibodies were induced by a procedure that differed from conventional immunization with Dex, it seemed relevant to study their class composition.
The main finding was that the heavy chain class composition of the Ab 1' antibodies was highly restricted. IgG1 together with IgM represented the bulk of the response, with IgG1 by itself as the major class representing 70% of the Abl' antibodies ( Fig.  5 a) . This was in contrast to the BALB/c primary and hyperimmune anti-a(l-3) Dex . 4 ); C.B20 (anti-Ab2) anti-B1355-Con A: anti-IdX-treated and B1355-Con A boosted mice (see Fig. 4 ); BALB/c anti-B1355:7 d primary response; C.B20 (anti-NRabIgG) anti-B1355-Con A: NRabIgGtreated mice boosted with B1355-Con A (see Fig. 4 ). In C.B20 mice, the two anti-Dex antibodies were purified from the same sera (see text).
Relative Binding of Ab l' Antibodies to Dextrans*
response which was principally in the IgM class, whereas IgG1 was not detectable (Fig. 5 a) . After boosting of the C.B20 mice with B1355-Con A (see Fig. 4 ), the proportion of the IgGl antibodies fell to 6-35% of the heavy chain classes, and was replaced by IgM as the major class (Fig. 5 a) . However, even then IgG1 still represented a sizeable proportion of the response. This class was not detectable in any of the a(1-6) specific antibody samples purified from the same sera (Fig. 5b) , or from the sera of mice injected with NRabIgG. Here, the response was mainly in the IgM class, with some previous occasions (33, 34) .
IgG3. As to the light chains, )kl was the only light chain type found on the Abl' antibodies, except for one C.B20 pool in which 20% of the response was composed of x chains. The occurence of a ~¢ anti-a(1-3) Dex component was also reported on
The class composition of Ab3 Ig is shown in Fig. 6 . This was determined on seven individual C.B20 sera or serum pools from the post-B1355-Con A boost period. The sera were preabsorbed on columns of B 1355 and B512, and on a column of NRablgG before being titrated on anti-J558-coated microplates (see Materials and Methods). As in the case of the Abl' antibodies, these IdX-positive Ig were also largely represented by the IgG1 class. Taken together, these results indicate that the IgG1 class represents a major component of the C.B20, C57B1/6 Abl', and Ab3 responses. F[o. 6. Relative percentage of isotype composition of Ab3 Ig in whole sera (see text for assay procedure). C,B20 (anti-Ab2)anti-B1355-Con A: anti-IdX-treated and B1355-Con A boosted mice (see Fig. 4 ) ; BALB/c anti-B 1355: hyperimmune BALB/c anti-B 1355 serum pool. expression with Igh-C a is now well established (2, 3) . It thus appeared paradoxical at first hand that this idiotype was found associated with A b l ' antibodies of C.B20 and C57B1/6 mice known to be Igh-C b homozygous. The lgh-C allotype of pre-immunization sera of the C.B20 mice used in this study was verified by Ouchterlony gel diffusion using polyvalent anti-Igh-C a and anti-Igh-C b allogeneic sera and all were typed homozygous Igh-C b. We next investigated the allotype of purified IdX-positive IgG1 antibodies. C.B20 A b l ' antibodies purified from two pre-B1355-Con A and from four post-B1355-Con A boost pools (see Fig. 4 ) were tested in parallel in an assay for the Igh4 b and an assay for Igh4 a allotype determinants. The results shown in Fig. 7 indicate that the antibodies were inhibitory in the assay for the Igh4 u allotype. There was no detectable inhibition in the Igh4" allotype assay (not shown). This indicates that the IgG1 component of the Abl' comes entirely from the Igh-C b haplotype.
A possible inhibition by contaminant normal serum IgG1 in these experiments was excluded by the following. Several Abl' antibody pools, chosen for high (80%) IgG1 antibody content, were divided into equal aliquots and absorbed with anti-x, anti-hi, or anti-IdX 558 antibodies coupled to Sepharose. The supernatants were then retested in the allotype assay. The allotype inhibitory activity was completely removed only with the anti-ha and the anti-IdX gels, but to no significant extent by the anti-x gel (not shown). This then strongly suggested that all of the IgG1 antibodies typed as Igh4 b expressed the IdX determinant.
Discussion
The essential findings reported here show that the C.B20 and C57B1/6 mice respond with sizeable IdX-positive Ig (Ab3) and IdX-positive anti-a(1-3) Dex antibody (Ab 1') components after injections of rabbit anti-IdX 558. The antibodies were defined as Abl' because of their idiotypic relatedness with the responder BALB/c IdX-positive anti-a(1-3) Dex antibodies (Ab 1), in analogy to a previously established nomenclature (24, 25) . The anti-IdX antibodies thus acted by altering the phenotype of the response of these animals to the a(1-3) Dex glucosidic linkage, since previous studies indicated that conventional immunization with Dex B1355 leads to either an IdX-negative anti-a(1-3) Dex response (2, 7) or to no detectable response in C.B20 mice (present study).
Le Guern et al. (12) , Bona et al. (11) , and Hiernaux et al. (35) , have similarly found that Ab2 can act by inducing an Id-positive antibody response in animals not expressing this Id upon conventional immunization. In all cases the Ab2-induced Id was shared by antibodies having the same antigen-binding activity in responder mouse strains. Furthermore, a similar approach to ours, using heterologous Ab2, was reported by Miller et al. (13) . When pig Ab2 specific for an Id found on BALB/c antinuclease antibodies were injected into B t0.D2 mice, the latter responded with Ig expressing this Id. The Id was absent from antinuclease antibodies induced by conventional immunization of B 10.D2 mice with staphylococcal nuclease.
It was particularly important to determine the IdX-specificity of the rabbit reagent used in the idiotypic characterization of the Abl', as a previous work as well as the present study indicated that C57B1/6 mice can respond with high titers of hi-bearing, but IdX-negative anti-a(1-3) Dex antibodies after conventional immunization with B1355-Con A (7) . This was done by testing the anti-IdX reagent against a panel of reference anti-a(1-3) Dex myeloma and hybridoma antibodies (6) . Only the IdXpositive antibodies were effective competitors in the IdX assay. Our reagent thus had a similar IdX-specificity than that reported by Hansburg et al. (5) and by Clevinger et al. (6) . Additionally, we have purified conventional C57B1/6 anti-a(1-3) Dex antibodies using the protocol ofGeckeler et al. (7) and found these to be IdX-negative in our assay, confirming the results of a different assay (7) . The conventional antibodies were thus clearly distinguishable from Ab 1' antibodies induced by Ab2 in the same strains of mice. We were thus confident that, as far as idiotypic relatedness is concerned, the Ab2-induced Ab 1' were indistinguishable from the responder BALB/ c Abl and the reference IdX-positive myeloma and hybridoma antibodies. These results argue strongly for the existence of a nonexpressed or "silent" anti-a(1-3) Dex repertoire in Igh-C b mice (36) .
INDUCTION OF A J558 CROSS-REACTIVE [DIOTYPE-POSITIVE RESPONSE
In the assay for IdX-positive Ig in whole sera it was important to determine the possible interference of any residual rabbit anti-IdX Ab2. Indeed, we and others (24) found that anti-ldX can combine with the radiolabeled proband ligand and thus mimic the effect of competitor IdX-positive molecules. For this, the sera were preabsorbed with various immunoabsorbents before being tested for IdX expression. The inhibitory activity was not eliminated by the J558 absorbent, indicating little if any residual rabbit Ab2. On the other hand, the elimation of inhibitory activity by the anti-N1 and anti-IdX absorbents indicated that IdX-positive Ig were being measured in the IdX assay and furthermore that most of them bore the 7~1 light chain.
In addition to Abl', the Ab2-treated C.B20 and C57B1/6 mice also responded with relatively large amounts of IdX-positive Ig (Ab3), which lacked detectable binding activity to Dex B1355 or B512. In contrast to Abl', they appeared to lack the full Id complement of the reference J558 myeloma protein. Ab3 Ig have been reported as either anti-(anti-Id) antibodies (12, 25) , i.e., directed against certain idiotopes expressed by the inducing Ab2 antibodies, or as Ig that express a part of the idiotopes present on responder Abl antibodies (11, 24) . It is considered that Ab3 and Ab2 express complementary idiotopes (11, 37) . As concerns the a(l-3) Dex system, the later definition for Ab3 may be more appropriate, This is based on the finding that Ab3 successfully competed in an IdX assay using either a rabbit or a mouse anti-J558 reagent, seen with Ab3 induced with either one of the anti-Id reagents. Similar findings were reported for Id-bearing Ig in the staphylococcal nuclease system (38) and in the p-azophenylarsonate (39) system. The a(1-3) Dex system also enabled us to include the light chain marker with which to define these molecules (2) . With only one exception, all tested samples of Ab3 Ig were found to bear exclusively this light chain type, which additionally suggested their strong molecular similarity with the responder anti-a(l-3) Dex antibodies. Ab3 Ig have been described in several other related studies in both the rabbit and mouse (12, 24, 25, 38, 40) . The true identity of the IdX-positive Ab3 Ig is still not fully understood, and studies are in progress to further characterize them.
It is revealing that Abl' were detectable in C.B20 and C57B1/6 mice without prior intentional immunization with Dex. Similar observations were recently reported in which a single injection of anti-Id led to the appearance of Ig with specific antigenbinding activity (39, 41, 42) although in those studies the animals were genetic responders. It has been proposed that an Id-positive response can be induced directly by anti-Id by reacting with regulatory idiotopes (11) expressed on the membrane of B cell precursors. The hypothesis further assumes that the antigen-specific precursors constitute a subpopulation of a larger Id-positive precursor pool (11, 43) . In the present study an inductive role played by endogenous flora microorganisms can not be excluded. For example, intestinal coliform saprophytes carrying cell wall Dex (44) could also have contributed to the induction of Abl' by further expanding the Ab 1' precursors. The delayed appearance of Abl' with respect to Ab3 would be consistent with this proposition. A similar view was held by Wysocki and Sato (39) in a study of the arsonate system.
On the other hand, it can not be decided to what extent an internal image (10) or a homobody (45) effect of anti-Id influenced the induction of Abl'. In previous studies, such properties of anti-Id were indeed described (46) . The immunochemical characterization of the rabbit and allogeneic anti-Id (see Materials and Methods) indicated that for approximately equal amounts of IBCs0 injected per animal, the IdX response of mice receiving the allogeneic anti-J558 was erratic and of low magnitude. In contrast, in all mice injected with the rabbit anti-IdX the response was more intense and rapid. To what extent this was related to the different relative anti-IdI J558 vs. anti-IdX specificities in the two anti-Id, or to their relative content of anti-binding site specificity (homobody), is not known. The response does however appear to correlate with the IdX-specificity content in the two reagents, since the rabbit compared to the mouse reagent was 100 and 25% IdX-specific, respectively.
It is significant that the Abl' levels of the Ab2-treated and B1355-Con A-boosted C.B20 mice did not reach the amounts found even in the primary conventional BALB/c response (~800 ~g/ml). One can assume that the Igh-Cb-linked nonexpression of IdX in these mice reflects the participation of T suppressor cells as was described in other genetically linked nonresponse systems (19, 47) . Thus, if specific T suppressor activity had been abolished by Ab3, as was shown in the Id 460 system (19) , only some of the T cell activity may have been inactivated. In other words, only the anti-IdX-receptor-bearing T cells would be targets of Ab3, whereas other T suppressors, specific for IdX-negative precursors, would remain functional and actively suppress this arm of the anti-~x(1-3) Dex response.
The early appearance of Ab3 1 wk after the second injection of Ab2, and the fact that a large fraction of this response was of the IgG 1 class, suggests an involvement of T helper cells in the inductive process. The fact that IgG1 is a prominent component of many secondary responses that involve T cell help (48) and is strongly thymus dependent (49) further attests to this possibility. Ab2-presensitization of these mice appears to have changed the nature of this TI-2 type response (50) into a thymusdependent response.
Previous studies where anti-Id (13, 51) or Id (52) was injected in vivo have implicated the participation of T helper cells. In the present system, the T helper cells may recognize regulatory idiotopes (11) shared by Igh-C a and Igh-C b anti-a(1-3) Dex antibodies. For example, Gleason and KShler (53) have shown that PC-induced T helper cells recognize shared idiotopes on two PC-binding myeloma antibodies M167 and T15, each of which is specifically distinguished by anti-Id sera. Suggestive evidence that C57B1/6 and BALB/c anti-a(1-3) Dex antibodies express regulatory idiotopes stems from recent experiments by C. Victor and C. Bona (personal communication) who achieved the total suppression of anti-a(1-3) Dex synthesis in C57B1/6 mice injected at birth with nanogram quantities of either monoclonal CD5-3 anti-IdX 558 or monoclonal EB3-7.2 anti-Id 558 antibodies.
The finding that C.B20 mice used an Igh-C b haplotype product for the synthesis of their IgG1 Abl' was not unexpected since these mice are homozygous for this heavy chain linkage group (3) . In view of the tight linkage of the heavy chain locus (54) , it is conceivable that the IgM and IgG3 class Abl' are likewise products of the same haplotype. Based on the well established linkage of allotype to idiotype of many antibody responses in the mouse (1, 3, 55) , this suggests that the Vn DeX gene product of these mice is coded by a different gene than that which codes for the VH Dex product in BALB/c mice. The remarkably reproducible differences in Dex-binding specificity of the Abl' compared with Abl is compatible with this hypothesis. Relevant to this is the description by Lieberman et al. (56) of PC-specific myeloma proteins from BALB/c and C57B1/6 which displayed minor Vn framework structural differences, and could be distinguished by appropriate anti-Id sera. The VH markers of these antibodies behaved as allelic variants in the PC response of various mouse strains. The confirmation of the present findings at the hybridoma level should add to our understanding of regulatory processes.
Summary
The effect of IdX-specific rabbit and allogeneic antiidiotype antibodies (Ab2) was investigated in vivo in Igh-C b mouse strains with respect to the induction of a crossreactive idiotype (IdX)-positive anti-a(1-3) Dextran (Dex) response. These C.B20 and C57B1/6 mice have an allotype-linked incapacity to respond with IdX-positive antia(1-3) Dex antibodies upon conventional immunization with Dex B1355. 7 d after the rabbit Ab2 injections, IdX-positive Ig (Ab3) and IdX-positive anti-a(1-3) Dex antibodies (Ab 1') were detected in the sera of each tested mouse. The affinity-purified Abl' were idiotypically indistinguishable from reference BALB/c IdX-positive myeloma proteins and BALB/c anti-a(1-3) Dex antibodies (Abl) in a competitive inhibition radioimmunoassay, while Ab3 Ig appeared idiotypically deficient and did not bind to Dex. The response to the a(l-6) linkage of Dex was not affected in these mice. A large fraction of the Abl' and Ab3 responses of both mouse strains were of the IgG1 class. The Abl' antibodies differed from BALB/c Abl by lower relative binding to five of eight tested Dex, and by expressing the Igh4 b allotype determinants on the IgG1 antibodies. This study identifies the products ofa V, Dex gene that appears to be under regulatory control in the Igh b mice. Its association with the b haplotype suggests that this gene may differ structurally from the BALB/c V. I~ex gene.
